• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

谁应该优先获得公共资金?

Who should be given priority for public funding?

机构信息

School of Pharmacy, Gyeongsang National University, Jinju, South Korea; Institute of Pharmacy, Gyeongsang National University, Jinju, South Korea.

Health Insurance Research Institute, National Health Insurance Service, Wonju, South Korea.

出版信息

Health Policy. 2020 Oct;124(10):1108-1114. doi: 10.1016/j.healthpol.2020.06.010. Epub 2020 Jun 26.

DOI:10.1016/j.healthpol.2020.06.010
PMID:32651005
Abstract

BACKGROUND

This study explored if Koreans consider the type of disease, rarity, and availability of alternative treatments as priority criteria in limited healthcare resource allocation.

MATERIALS AND METHODS

A web-based survey was conducted with a representative sample of 3,482 Korean adults. Participants were divided into six cohorts, differing in terms of the disease being compared and the cost and benefits of the treatments. Each cohort was asked two questions: 1) How to allocate a fixed budget into each of the two groups (cancer vs non-cancer, rare vs common, no other treatments available vs several treatments available), all else being equal; 2) allocation choices when conditions of two groups differed. The McNemar test was used to assess changes in responses between the two questions.

RESULTS

Under the control condition, the majority chose to treat an even number of patients with cancer and non-cancer diseases, and preferred to treat common diseases and those with no alternative treatments. However, when the treatment effects or costs of two comparison groups changed, choice shifted toward more effective or less costly treatment.

CONCLUSIONS

While Koreans generally support the principle of health maximization, they also believe that priority should be given to diseases that previously did not have any treatments. However, no priority was given to cancer or rare diseases.

摘要

背景

本研究探讨了韩国人在有限的医疗资源分配中是否将疾病类型、罕见程度和替代治疗方法的可及性视为优先标准。

材料和方法

采用基于网络的调查方式,对 3482 名韩国成年人进行了代表性抽样调查。参与者被分为六个队列,根据比较的疾病、治疗的成本和收益而有所不同。每个队列都被问到两个问题:1)在所有其他条件相等的情况下,如何将固定预算分配到两组(癌症与非癌症、罕见与常见、无其他治疗方法与有几种治疗方法);2)当两组条件不同时的分配选择。采用 McNemar 检验评估两个问题之间的回答变化。

结果

在对照条件下,大多数人选择治疗癌症和非癌症患者的人数相等,并倾向于治疗常见疾病和无替代治疗方法的疾病。然而,当两个比较组的治疗效果或成本发生变化时,选择倾向于更有效或成本更低的治疗方法。

结论

尽管韩国人普遍支持健康最大化原则,但他们也认为应优先考虑以前没有任何治疗方法的疾病。然而,癌症或罕见疾病并没有得到优先考虑。

相似文献

1
Who should be given priority for public funding?谁应该优先获得公共资金?
Health Policy. 2020 Oct;124(10):1108-1114. doi: 10.1016/j.healthpol.2020.06.010. Epub 2020 Jun 26.
2
Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.让加拿大公众参与罕见病药物报销决策:一项全国性在线调查。
BMC Health Serv Res. 2017 May 26;17(1):372. doi: 10.1186/s12913-017-2310-4.
3
Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults.公众对健康干预措施预算分配的优先顺序设定标准的偏好:对伊朗成年人调查的结果。
BMC Public Health. 2022 Nov 8;22(1):2038. doi: 10.1186/s12889-022-14404-1.
4
Comparison of Rare and Common Diseases in the Setting of Healthcare Priorities: Evidence of Social Preferences Based on a Systematic Review.医疗保健优先事项背景下罕见病与常见疾病的比较:基于系统评价的社会偏好证据
Patient Prefer Adherence. 2023 Jul 24;17:1783-1797. doi: 10.2147/PPA.S416226. eCollection 2023.
5
Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia.社区对影响药品资源分配因素的看法:对澳大利亚3080名成年人的横断面调查。
Aust Health Rev. 2019 Jul;43(3):254-260. doi: 10.1071/AH16209.
6
General public's understanding of rare diseases and their opinions on medical resource allocation in Japan: a cross-sectional study.公众对罕见病的认知及对日本医疗资源配置的意见:一项横断面研究。
Orphanet J Rare Dis. 2023 Jun 8;18(1):143. doi: 10.1186/s13023-023-02762-x.
7
Prioritizing Rare Diseases: Psychological Effects Influencing Medical Decision Making.优先考虑罕见病:影响医疗决策的心理效应
Med Decis Making. 2017 Jul;37(5):567-576. doi: 10.1177/0272989X17691744. Epub 2017 Feb 14.
8
Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.英国成年人对 NICE、癌症药物基金以及基于价值的药物优先排序定价标准的看法:一项对 4118 名成年人的横断面调查。
Health Econ. 2013 Aug;22(8):948-64. doi: 10.1002/hec.2872. Epub 2012 Sep 7.
9
Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors.优先治疗罕见病:挪威医生偏好的调查。
Soc Sci Med. 2013 Oct;94:56-62. doi: 10.1016/j.socscimed.2013.06.019. Epub 2013 Jun 26.
10
Rare diseases in healthcare priority setting: should rarity matter?医疗保健中的罕见病优先排序:罕见性重要吗?
J Med Ethics. 2022 Sep;48(9):624-628. doi: 10.1136/medethics-2020-106978. Epub 2021 Jun 8.

引用本文的文献

1
Views and opinions of the general public about the reimbursement of expensive medicines in the Netherlands.荷兰公众对昂贵药品报销的看法和意见。
PLoS One. 2025 Jan 8;20(1):e0317188. doi: 10.1371/journal.pone.0317188. eCollection 2025.
2
Comparison of Rare and Common Diseases in the Setting of Healthcare Priorities: Evidence of Social Preferences Based on a Systematic Review.医疗保健优先事项背景下罕见病与常见疾病的比较:基于系统评价的社会偏好证据
Patient Prefer Adherence. 2023 Jul 24;17:1783-1797. doi: 10.2147/PPA.S416226. eCollection 2023.
3
Can cancer go green? It's up to us.
癌症能走向绿色环保之路吗?这取决于我们。
Front Oncol. 2023 Feb 22;13:1074091. doi: 10.3389/fonc.2023.1074091. eCollection 2023.
4
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.罕见病治疗方法的评估:社会偏好研究的系统文献综述。
Adv Ther. 2023 Feb;40(2):393-424. doi: 10.1007/s12325-022-02359-z. Epub 2022 Dec 1.
5
Can We Afford to Exclude Patients Throughout Health Technology Assessment?在整个卫生技术评估过程中,我们能承担得起将患者排除在外的后果吗?
Front Med Technol. 2022 Jan 25;3:796344. doi: 10.3389/fmedt.2021.796344. eCollection 2021.